Two days ago, Novo Nordisk handed Jiangsu Hengrui Pharmaceuticals $300 million upfront for HRS-1596, an oral GLP-1/GIP dual agonist that has approval in China to initiate Phase 1 trials. Total deal value reaches up to $2.6 billion contingent on development, regulatory, and commercial milestones, with Novo securing exclusive rights to develop, manufacture, and commercialize the drug globally, excluding mainland China, Hong Kong, Macao, and Taiwan. The drug is early. The price is not.
BMO Capital Markets analyst Evan Seigerman said the transaction is unlikely to shake up near-term competition, but called the candidate an attractive longer-term pipeline option for the Danish drugmaker. That is a polite way of saying Novo paid a billion-dollar entry fee for an asset that will not move the needle before 2030. The reason it did so anyway tells you everything about where the weight-loss arms race has gone.
The deal helps Novo shore up its competitive position against rivals such as Eli Lilly, with several patents set to expire in the next decade, and Novo’s shares are down roughly 70% from their 2024 peak amid intensifying competition in obesity. Acquiring early-stage insurance from Chinese developers is the cheapest option left. Nearly 250 Chinese GLP-1 candidates are under development, according to data provider PharmCube, and major global drugmakers including AstraZeneca, Merck, and Pfizer have struck rights deals with Chinese developers.
The Deal Math Keeps Escalating
The Hengrui transaction is the latest sign that Novo is willing to pay up for earlier-stage obesity shots on goal. In March 2025, it agreed to pay $200 million upfront and up to $1.8 billion in milestones for the rights outside Greater China to UBT251, an early experimental triple agonist being developed by United Laboratories International. That candidate, UBT251, showed mean weight loss of up to 19.7% after 24 weeks in a Phase 2 trial in China that Novo says was jointly developed. The more promising the data, the more expensive the next check. At least eight mega-deals in the GLP-1 and obesity space were announced in 2025, with total deal values exceeding $50 billion, making it the most active therapeutic area in the biotech licensing deal tracker.
Pfizer set the ceiling. After a late-2025 bidding war with Novo Nordisk, Reuters reported Pfizer ultimately landed Metsera in an acquisition valued at about $10 billion. The bidder intensity alone signals how badly large-cap pharma needs late-stage obesity pipeline it does not have to build from scratch.
Viking Is the Last Big Independent Asset
Which brings you to Viking Therapeutics, and a valuation gap that grows harder to explain as the deal calendar fills. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not yet owned by big pharma, and Viking is a clinical-stage biotech with no revenue and a market cap around $3.6 to $3.8 billion.
The VANQUISH Phase 3 program has enrolled more than 4,500 patients, and Viking announced in March 2026 that VANQUISH-2 completed enrollment in the first quarter of 2026.
Viking carries a 38.5% implied probability of being acquired before 2027 on Polymarket, based on a contract that has drawn more than $1.68 million in volume. With about $501.7 million in cash and short-term investments as of June 30, 2026, and a market cap in the mid-$3 billions, Viking is small enough to swallow and dangerous enough that Novo cannot afford to let Lilly grab it. Wall Street consensus sits at $92 against a stock trading well below $35.
Viking also expects to begin Phase 3 studies of an oral formulation in the fourth quarter of 2026. Every quarter that passes without a deal is a quarter in which Phase 3 data compounds the eventual acquisition price. Novo just demonstrated it will pay up to $2.6 billion for a drug that is only now entering Phase 1. Viking has 4,500-plus patients enrolled. The arithmetic points in one direction.
What Traders Watch Next
- VANQUISH-1 data timeline. Phase 3 readouts are expected in the 2027-2028 window. A strong interim or early completion would immediately reset the bid calculus.
- Oral Phase 3 start. Viking’s oral VK2735 Phase 3 launch in Q4 2026 adds a second asset to any acquisition conversation, widening the price floor.
- Novo’s next move. Novo Nordisk has a problem: it generates most of its revenue from diabetes and obesity products, and stiff competition from Eli Lilly in these markets has pressured expectations. A defensive acquisition of Viking would be the most direct fix available.
- Antitrust optics for Lilly. Eli Lilly reported Q1 2026 revenue of $19.8 billion, up 56% year over year, with Mounjaro and Zepbound leading. A second platform still adds optionality, even if antitrust optics complicate the fit.
The Hengrui deal confirms one thing: there is no price too high for a credible obesity pill with a clean clinical path. Viking has one. The clock is running.
